This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
During 2023, drugmakers substantially raised prices on five widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $815 million last year, according to a new report.
If David Ricks is the best biopharma CEO of 2023 , then Pfizer CEO Albert Bourla is, unfortunately, the worst. Pfizer is this year’s anti-Eli Lilly. My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability.
Health care stocks stumbled compared with the rest of the market in 2023. Even in a down year, the median health care CEO made 51 times the median American household income, which was around $81,000 in 2023. Companies missed their profit targets. Some CEOs even lost their bonuses. But the biggest names in health care still made $3.5
It’s the standard notice many health care organizations are required to provide when your protected health information gets exposed — and in 2023, data leaks, hacks, and mishandling led more of them to be delivered than ever before.
The study, which estimated childhood vaccination coverage between 1980 and 2023 in 204 countries and territories, found that the Covid-19 pandemic significantly intensified existing immunization challenges. Read the rest…
Rates of mental illness and substance use remained largely stable in 2023, according to federal data, underscoring the severity of the long-running U.S. mental health crisis and worst-in-the-world rates of illicit drug use. And while overall rates of nicotine use also remained roughly even, the way people consumed it shifted slightly.
Let’s get right to the main course: David Ricks of Eli Lilly is the runaway, rock star, who-else-could-it-be Best Biopharma CEO of 2023. More on those high-achieving folks later. What an incredible year it’s been for Ricks and the Lilly executive team who helped him achieve so much.
That trend of vertical integration was on full display in 2023, a year when the country’s biggest pharmacy chain bought a primary care provider, and the biggest private insurer branched further into home health. Companies that were once just insurers or just pharmacies are tacking on new business lines.
Merck’s Keytruda has been used against dozens of different cancers in millions of patients, making it the top-selling drug in the world, with over $25 billion in revenue in 2023. Opdivo, from Bristol Myers Squibb, earned $10 billion in 2023.
Continuing economic uncertainty and the threat of a recession are casting a pall over health tech in 2023 — a dramatic shift for an industry that enjoyed abundant funding in the pandemic’s early stages.
That is similar to what the company has been saying since June 2023. The higher use of care among these Medicare enrollees “was most notable within physician and outpatient services,” UnitedHealth said in its first-quarter earnings release.
LONDON — Three scientists whose work on electrons widened the world’s understanding of the particles’ behavior inside atoms and molecules won the 2023 Nobel Prize in physics on Tuesday.
For the moment, the state has not fined the company, although it may yet do so, according to a consent order. A department spokesperson declined to comment. However, the audit was released two months after Express Scripts had been ordered to pay a $250,000 fine for failing to reimburse a pharmacy.
It was first filed in 2023 after a series of STAT stories revealed the company’s practices. District Court in Minnesota, alleges that UnitedHealth and its subsidiary NaviHealth relied on flawed algorithms to cut off essential rehabilitative care to sick and injured Medicare Advantage beneficiaries.
LONDON — The 2023 Nobel Prize in chemistry was awarded Wednesday to three scientists for the discovery and synthesis of quantum dots, tiny particles that have fueled innovations in nanotechnology from televisions to mapping different tissues in the body.
During an April 2023 inspection at Raptim facilites in Nava Mumbai, India, FDA inspectors found “objectionable conditions” that led them to conclude the company falsified data in testing for multiple subjects and samples across multiple studies, according to a letter sent last week to the pharmaceutical companies.
Even worse, 9% of 9th through 12th graders attempted suicide in 2023, reflecting our nationwide teen mental health crisis. Youth depression has practically doubled over the past decade. Read the rest…
However, between 2013 and 2023, private equity firms made over 1,000 acquisitions of disability and elder care providers — a likely undercount, according to the report published by the Private Equity Stakeholder Project, a nonprofit watchdog focused on the growing impact of the private equity industry.
The resulting pet food industry is massive — Americans spent $65 billion on pet food and treats in 2023 alone. More than 102 million U.S. households own a dog or a cat, and thousands more have fish, birds, or reptiles. Read the rest…
When Ted Matthews came out of retirement in early 2023 to retake the helm of the rural Texas hospital where he’d started his health care career, it was something of a rescue mission. And yet, just 38 hospitals have taken up the new designation since 2023, fewer than researchers had predicted.
The number of ongoing and active drug shortages in the U.S. stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country.
In 2024, about 8% of pediatrics positions went unfilled , an increase from about 3% in 2023. It also tells the rest of us what fields of medicine are having trouble attracting new physicians. Meanwhile, children’s hospitals report large numbers of vacancies in many pediatric subspecialties. All
The first cycle of negotiations resulted in meaningful projected savings for Medicare and for people with Medicare — an estimated $6 billion for the program if the negotiated prices were in place in 2023 for the first 10 selected drugs, and $1.5
a nonprofit that drew $178 million in revenue in 2023, the latest year for which data are available, and spent half that money on marketing. Department of Agriculture and funded by dairy farmers and importers whose mission is to promote dairy consumption. It’s run by Dairy Management Inc.,
And just like in 2023, UnitedHealth has prioritized outpatient surgery centers. The sprawling conglomerate — which owns a major health insurance company, physician practices, a pharmacy benefit manager, and numerous other firms — acquired or created more than 250 subsidiaries in 2024.
WASHINGTON — Pharmaceutical giant AbbVie paid health care providers roughly $145.7 million last year to promote its drugs, according to a STAT analysis of newly released government data.
pharmaceutical industry rose last month and, overall, the rate at which jobs have been shed this year continues to outpace what occurred in 2023 , according to Challenger, Gray & Christmas, the outplacement and executive coaching firm. A The number of layoffs in the U.S.
The net prices that health plans paid for medicines — after subtracting rebates, discounts, and fees — fell by 2.8% in last year’s fourth quarter, the largest decline ever measured by SSR Health, a research firm that tracks the pharmaceutical industry and its pricing trends.
In 2023, enrollment in Medicare Advantage, the version of Medicare run by private insurers, surpassed 50% of eligible beneficiaries for the very first time. Companies like CVS Health and UnitedHealth Group saw losses of 5.2% respectively, while Humana, whose business model relies heavily on the MA program, fell an astonishing 14.2%.
Health tech investments are showing signs of resilience following the perilous lows of 2022 and 2023: Just this past month, two startups that analysts believe might be getting ready for IPOs raised more than $100 million in late-stage funding rounds.
The results are notable because the drug, tecovirimat, has rarely been studied clinically for mpox, despite its sporadic use over the years in parts of Africa and its wider use during the 2022 and 2023 outbreaks in the U.S. and Europe. Read the rest…
In December 2023, a groundbreaking announcement grabbed headlines : After years of anticipation, the Food and Drug Administration approved the first gene therapies for treating sickle cell disease, offering hope of eliminating life-altering symptoms.
uninsured rate in 2023 was a record low at the time, but didn’t factor in any of the people who were losing their Medicaid coverage. The national uninsured rate rose from 7.7% Read the rest…
The drug, known as Pemgarda and marketed by the biotech Invivyd, is the first such drug to become available since the agency pulled AstraZeneca’s Evusheld off the market in January 2023. New Omicron variants had rendered Evusheld ineffective. Read the rest…
The two-year suspension was issued on March 16, 2023, by the Association of British Pharmaceutical Industry after receiving a complaint alleging the company sponsored courses on weight management on LinkedIn for health professionals, without making clear that it was involved in the sponsorship.
In 2023, Kentucky became the most recent state to pass a law prohibiting the denial of organ transplantation to patients solely because of their marijuana use. The legislation is scheduled to go into effect Jan. Over the past 11 years, similar measures have been enacted in 21 other states.
It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. The device maker bought Apollo Endosurgery , a company selling surgical tools to combat obesity, for $615 million in 2023. The deal is worth $3.7
A persistent theme for health insurance companies throughout 2023 has been their Medicare Advantage members using more care than their actuaries projected, which has been eating into the profits they get from federally funded health care premiums.
from an assessment of a related virus conducted in April 2023. The new assessment , developed using the CDC’s influenza risk assessment tool or IRAT, gauged the risk the virus might someday cause a pandemic at 5.79, up from a previous score of 5.12 Both numbers are within what the CDC tool terms a “moderate” risk of 4.0
The genetic data point to a single spillover event that probably occurred in late 2023, Michael Worobey, an evolutionary virologist at the University of Arizona, told STAT on Tuesday. Department of Agriculture. Read the rest…
Specifically, the average shortage lasted for more than three years in 2023 compared to about two years in 2020, and 27 of the 125 drugs in short supply were not available for more than five years. And 53% of new shortages occurred among generic sterile injectable medicines, according to the report from U.S.
of biomedical scientists who had a job lined up were bound for industry in 2023. As the proportion of industry-bound researchers dipped in 2023, the percentage of graduates going into academic jobs increased from 18.8% graduates, show that 61.6% That’s a sizable dip from 66.5% in 2022 to 22.1%. in 2022 to 22.1%.
269
269
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content